{"name":"Shaperon","slug":"shaperon","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HY209 0.5%","genericName":"HY209 0.5%","slug":"hy209-0-5","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"HY209 0.5%","genericName":"HY209 0.5%","slug":"hy209-0-5","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOU1lWRWFPWjJpRzIzVEEtOEVGWGdtWng1MmIxaVdOMFU0bDRkXzhuSUx1dWI5elp2c0VtZ0VBRGs2WW8wOXRKRHBaUnJscUZZU3VOeVJvb0Q3ZUxZOHhVQnBBb2FwWE1mV252ZTdOanF1anEtVGZvYWtpaGhVUk85bkVvQ3ZnRjBBb0JSZEEtMVNjUQ?oc=5","date":"2026-01-15","type":"pipeline","source":"BRIDGE（ブリッジ）","summary":"Compliance AI Platform “Shaperon” Completes Series B Round - BRIDGE（ブリッジ）","headline":"Compliance AI Platform “Shaperon” Completes Series B Round - BRIDGE（ブリッジ）","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"GlobeNewswire","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBnWUY0UE4yU0V3Mm9SeDhQbkEzNFBzbzhYSHRuOEZMNkZoZGozZ2NoeGptbWhycjhDZG0yd1JwS2lIcV9iRDBINm1FcE1sbXUwd0tj?oc=5","date":"2025-12-01","type":"pipeline","source":"FirstWord Pharma","summary":"Protego pulls in $130M to tackle AL amyloidosis at its molecular root - FirstWord Pharma","headline":"Protego pulls in $130M to tackle AL amyloidosis at its molecular root","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE11R0tQd3dZWktIbkZUZUNZN3dGMEFNbEVPR214b2RMakg3RkQzUWlfekRqOWtxRXBNUmtxZGlSR0ttSllNTDBEbDRxbmVsZllEY0J6TnlZRGQ2emVEbHFr?oc=5","date":"2025-11-28","type":"pipeline","source":"Nature","summary":"Programmable targeted RNA degradation via dCas13d-directed chaperone-mediated autophagy (dCasCMA) - Nature","headline":"Programmable targeted RNA degradation via dCas13d-directed chaperone-mediated autophagy (dCasCMA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQd3FBTE9tSFhFOG1MMTJyZDNuSFc4aHdYY1paY0RYN0pGdXdKZF9KMG9XdWJoS3d6QnFjTVF3QUhBTjZYcEV6TEdrUUREcjF0Sjk0TTIwbzF3UDN3bk9BNmpPSGh1bEhRMmJRTUxJM0s0T3lKeEFTcVFGSVVqbTVoT1EzbzhpdVhzOUtldW8wTmtUdw?oc=5","date":"2025-05-20","type":"trial","source":"Yahoo Finance","summary":"Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - Yahoo Finance","headline":"Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPMXFsWjVfbDVrekV3X09xRTU1ZmV2VndpcDNGdXhlY08xTjJUT3J0OVBhajFnM1VRLU9WaHVELXpvbW5MQ1B6cDZCRXpxcURwcV91WVQ4eDJadHBMZEpuUW5pSUNTQXhlX2lKa0dXcUJDYVR4VHFDdEpvYnNGSjRWTE54Sm1WZW5IMTEwQ0hjdjdtTzF6R2lFVXpHMWVnYm9zc1BxbTRGeHo2MTJ0NElHbGtTNDByWlh4N21rSGpucGxrWjM1N3loR3prRG9qUWhnQ3dSRUFja2tOZWdoRzJpeU15d2U4d2FyUnlz?oc=5","date":"2025-03-10","type":"trial","source":"BioSpace","summary":"Hudson Therapeutics, the U.S. Subsidiary of Shaperon, Announces Initiation of Phase 2b Part 2 Clinical Trial for NuGel - BioSpace","headline":"Hudson Therapeutics, the U.S. Subsidiary of Shaperon, Announces Initiation of Phase 2b Part 2 Clinical Trial for NuGel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5qRlEydTJSNm03ekZOZUJRaEJfQVczT3J5UUFZYlN0ZmVSZ3JlUUJlMEREZk91Sl9naUlacmUxejM0UEpScUhvdHpNQUxDdE10aklB?oc=5","date":"2025-01-30","type":"trial","source":"FirstWord Pharma","summary":"Alterity surges after iron chaperone hits key goals in multi-system atrophy trial - FirstWord Pharma","headline":"Alterity surges after iron chaperone hits key goals in multi-system atrophy trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5oN0VUSVZjMFNZSGkxQzhkV2UxbVVvRGRkbDM3eXRRQzlDRThaQ2VvTEEtUjFkcGJadHUtSDNXcnVRaC1mNnNJeUhXUnhER2dTVmRjSlBKTXZyMkQ5U2F4WXFiV1Q1OXQyRzVENnB30gFyQVVfeXFMT1hfOWxIREpNekFzNVMxWkRCMmVsZnF3OFFiODBMS1VsdXdMV3diODk0OTlxVVFXcW51c29GVnl2QTNGZ3ZKTGw3NnRGM29DN0lucm4wTTUxc2Y5alpsS2ZvN1ZkbDFNbG04M1JoMndrM1FB?oc=5","date":"2025-01-23","type":"trial","source":"koreabiomed.com","summary":"Shaperon’s successful phase 2 trial results raise hopes for new atopic dermatitis drug - koreabiomed.com","headline":"Shaperon’s successful phase 2 trial results raise hopes for new atopic dermatitis drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNWUQteENvX2l3YnZLZmxObzZ1dlQtWmNPYmM3TFNvOXRPMW52a3NvYnU1LXFQSGg2NEw3amlpQVo2dlJFdUtLRmxzNTdkWENWNnhjaXM5aENCMjdjbTNQVDgwRmdmbHpSXy1obHkwTmhqMXRibzBJS3dUcmJjTzJnT3RmRzdGVE1iNEV6bV94S09mNVlpMFp5ZTZIZ0d3MTA?oc=5","date":"2024-06-11","type":"pipeline","source":"BioWorld News","summary":"Abtis tapping ADC market with Claudin18.2-targeting AT-211 - BioWorld News","headline":"Abtis tapping ADC market with Claudin18.2-targeting AT-211","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1aZVpzMlVKLXJyaG4zLXExM3Atd0R1R2poVHRRUFFqeVZrekEySmF1Z2dUb3pMQ09ISDdEaV85ZjJ2RkN0RWNsV1VUQWZVVTBMZnRxQjA5LVplUmFjNGNUbmdEVVBVUW1vSzFBYzBvTQ?oc=5","date":"2024-03-12","type":"pipeline","source":"Wiley Online Library","summary":"Targeted Degradation of Cell‐Surface Proteins via Chaperone‐Mediated Autophagy by Using Peptide‐Conjugated Antibodies - Shao - 2024 - Angewandte Chemie International Edition - Wiley Online Library","headline":"Targeted Degradation of Cell‐Surface Proteins via Chaperone‐Mediated Autophagy by Using Peptide‐Conjugated Antibodies - ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1NWGRhTWhRb21VdXNSMzhWVTNsRjJiaHdTZzFrQXdZVjRtSUVHMklQcXh1Z24ySnpIdm5pa3NqMlNqbl9DdENpX2ZEaklOeFdSV21qWlA3cmk0ZTFRa3NF?oc=5","date":"2023-09-07","type":"pipeline","source":"Nature","summary":"Congruence Therapeutics: finding a fix for misfolded proteins - Nature","headline":"Congruence Therapeutics: finding a fix for misfolded proteins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1KTmV3c2Nka1pnZzh0WEx4V3NhWlpXU1NpT3VXRnJKT1FOZnhYNHVXWUdsMXdmUllOVG5LRG82dmpNOExKQTdONEpudzFkNnU5Z0prMHM3LTB2SFRJTk1hOC1IT0xMa3hEZW9EQ0ZB0gFyQVVfeXFMTjg1MVZObTd2dnZFQ21YaHBhYTZNeGRzQTZRbnJKaUxFRkJPbXdpeFJubE0yOXc4MXE3Ukh6bk5veVJlamE2S3BvdnBVeGRLbzliYVphV1BabFNiaUhfWnI1SnBlS2RXbXE5Q05OOXdCazRR?oc=5","date":"2023-04-24","type":"pipeline","source":"koreabiomed.com","summary":"Shaperon to spend $2.3 million to set up US subsidiary in Boston - koreabiomed.com","headline":"Shaperon to spend $2.3 million to set up US subsidiary in Boston","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}